A5039703929- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Prostate Cancer Treatment and Research
- Inflammatory Biomarkers in Disease Prognosis
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Neutropenia and Cancer Infections
- Cancer-related Molecular Pathways
- Bacterial Identification and Susceptibility Testing
- Advanced Breast Cancer Therapies
- Sepsis Diagnosis and Treatment
Administração Regional de Saúde de Lisboa e Vale do Tejo
2025
Hospital de Santa Maria
2024
D’Or Institute for Research and Education
2017
Background Prostate cancer (PCa) encompasses a heterogeneous spectrum, ranging from indolent to highly aggressive forms, with approximately 10-20% of patients initially localized disease later becoming metastatic. Oligometastatic PCa (OMPC) represents an intermediate state between locally advanced and high-volume metastatic disease. Understanding the immune landscape OMPC plurimetastatic (PMPC) can provide valuable insights into biology, potential implications for treatment strategies...
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard-of-care for estrogen receptor (ER)-positive, HER2-negative (ER+/HER2- advanced/metastatic breast cancer (mBC). However, impact CDK4/6i on circulating immune cells and tumor (CTCs) in patients receiving ET (CDK4/6i+ET) remains poorly understood. This was a prospective cohort study including 44 ER+/HER2- mBC treated CDK4/6i+ET either first or second line. Peripheral blood samples...
Abstract Background: The occurrence of breast cancer in young women (BCYW), i.e., under 40 years old (<40 years), is increasing, and tumors this group often exhibit different biology prognosis compared to those older counterparts. Aim Study Design: This study aimed access the peripheral immune cell populations metastatic BCYW at diagnosis compare them with (≥40) (BC) patients. Blood samples were collected when disease was diagnosed before treatment began. Materials Methods: A total 90...
Abstract Background Cyclin Dependent Kinase inhibitors (CDKi’s) in combination with Endocrine Therapy (ET) have changed the first line management of patients most common subtype (HR+, HER2-) metastatic breast cancer (MBC), improving progression-free survival (PFS) and overall survival. However, approved indications for advanced cancer, approximately 20% been observed to no response CDKi’s ET, progress after starting these therapies. Unlike other targeted therapeutics, there is companion...